Green Thumb Industries (GTBIF) has seen its stock price decline over 80% from its 2021 peak, yet it remains a leading player in the U.S. cannabis market with 113 dispensaries across 14 states. Despite the broader struggles in the cannabis sector, characterized by a supply-demand imbalance and declining prices, Green Thumb reported robust financial results, including $1.2 billion in revenue for 2025 and a net income of $83.2 million in Q4, highlighting its operational strength.
The potential for a significant turnaround lies in the recent executive order signed by President Trump, which aims to reschedule cannabis to Schedule III. This change would allow Green Thumb to deduct ordinary business expenses under IRS Section 280E, significantly enhancing its profitability. Analysts are optimistic, with all eight covering the stock rating it a buy and projecting a 169% upside over the next 12 months.
For market professionals, Green Thumb represents a compelling opportunity in the cannabis space, particularly for those willing to navigate the inherent volatility while capitalizing on its strong financial foundation and upcoming regulatory changes.
Source: fool.com